According to TipRanks.com, Liu is ranked 0 out of 5 stars with an average return of -20.9% and a 20.0% success rate. Liu covers the Healthcare sector, focusing on stocks such as Monte Rosa Therapeutics, Nurix Therapeutics, and Cogent Biosciences.
Currently, the analyst consensus on Arvinas Holding Company is a Strong Buy with an average price target of $134.40, implying a 77.9% upside from current levels. In a report issued on February 9, Wells Fargo also initiated coverage with a Buy rating on the stock with a $98.00 price target.
Arvinas Holding Company’s market cap is currently $3.99B and has a P/E ratio of -19.85.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARVN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.
Read More on ARVN:
- Leerink Partners Remains a Buy on Provention Bio (PRVB)
- Editas Medicine (EDIT) Gets a Hold Rating from Leerink Partners
- RegenXBio (RGNX) Receives a Hold from Leerink Partners
- Sio Gene Therapies (SIOX) Gets a Hold Rating from Leerink Partners
- Leerink Partners Thinks Xencor’s Stock is Going to Recover